Related Experiment Video

Updated: Aug 9, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Effects of HER2-binding affibody molecules on intracellular signaling pathways

Lina Ekerljung1, Ann-Charlott Steffen, Jorgen Carlsson

  • 1Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala, Sweden.

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|May 3, 2006
PubMed
Abstract

Insights

Two novel affibody molecules targeting HER2-positive breast cancer showed distinct effects on cell signaling. ZHER2:342 demonstrated potential as a therapeutic agent for HER2-positive cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Human epidermal growth factor receptor 2 (HER2) is overexpressed in 25-30% of breast cancers.
  • HER2 is a tyrosine kinase receptor crucial for cell proliferation, migration, and apoptosis.
  • Targeting HER2 is a key strategy in treating HER2-positive breast cancers.

Purpose of the Study:

  • To investigate the effects of two novel HER2-binding affibody molecules, (ZHER2:4)2 and ZHER2:342, on intracellular signal transduction pathways.
  • To compare the biological effects of these affibody molecules with the clinically approved antibody trastuzumab.
  • To evaluate the potential of ZHER2:342 as an alternative or complement to trastuzumab for HER2-positive breast cancer treatment.

Main Methods:

  • Quantitative immunoblotting was used to analyze intracellular signal transduction pathways (Erk1/2, Akt, PLCgamma1).
  • Cell culture experiments were performed to assess biological effects, including growth and migration.
  • The effects of affibody molecules were compared to trastuzumab (Herceptin).

Main Results:

  • HER2 phosphorylation was induced by trastuzumab and (ZHER2:4)2, but inhibited by ZHER2:342.
  • (ZHER2:4)2 stimulated Erk1/2 and PLCgamma1 phosphorylation, cell growth, and migration.
  • ZHER2:342 inhibited PLCgamma1 phosphorylation and migration, demonstrating distinct signaling modulation compared to trastuzumab and (ZHER2:4)2.

Conclusions:

  • ZHER2:342, a 7 kDa agent, shows promise as an alternative or complementary therapy to trastuzumab for HER2-positive breast cancer.
  • The distinct signaling effects of ZHER2:342 suggest a unique therapeutic mechanism.
  • Radiolabeled ZHER2:342 could potentially be utilized for HER2-targeted imaging and radionuclide therapy.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Autocrine Signaling01:01

Autocrine Signaling

Autocrine signaling is one of the many signaling mechanisms that function inside multicellular organisms to carry out intercellular communication. In this type of signaling mechanism, the same cell that secretes an extracellular signaling molecule also expresses the receptors to bind and respond to that signaling molecule.
Autocrine Signaling in Macrophages
Under normal physiological conditions, autocrine signaling is essential for maintaining homeostasis. This process is well characterized in...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...